VIPC Regional Innovation Fund Grant Awarded to Charlottesville BioHub to Strengthen the Entrepreneurial Ecosystem in the Charlottesville Region

Funding will further Charlottesville BioHub’s goals to advance entrepreneurship in the area’s biotechnology sector and support tech and other innovation-led sectors with resourcing and connection

Charlottesville, Virginia – Charlottesville BioHub, an industry-led 501c3 nonprofit organization dedicated to strengthening Charlottesville’s biotechnology industry sector, today announced that it has received a $200,000 grant from the Virginia Innovation Partnership Corporation’s (VIPC) Regional Innovation Fund (RIF), an administered state-funded program that provides competitive grants to leading Virginia-based organizations that support entrepreneurship. Charlottesville BioHub is at the center of a thriving entrepreneurial ecosystem in the Charlottesville region, with many partners across economic development, industry, and academia.

Charlottesville BioHub’s Project InnoVAte aims to broaden the region’s network capital and connect high-growth, scalable startups in biotech, tech, and other innovation-led sectors to relevant programming and resourcing within the ecosystem.

“We are pleased to provide a Regional Innovation Fund grant to Charlottesville BioHub to support its efforts to strengthen Central Virginia’s biotechnology industry through engagement, resourcing, and education,” said Conaway Haskins, Vice President for Entrepreneurial Ecosystems at the Virginia Innovation Partnership Corporation. “The organization aims to double the size of the industry in its geographic footprint by 2030 by creating value and reducing barriers for companies to thrive and grow within the region. Over the past five years, Charlottesville BioHub has emerged as a linchpin to growing the region’s biotech and life sciences sector and it is serving as a model for other regional biotech hub efforts across Virginia.”

Project InnoVAte includes three initiatives:
• InnoVAte: An expanded Entrepreneurship-in-Residence (EIR) program will support company commercialization and business operations through education and advising for early-stage ventures.
• ActiVAte: Curated high-quality programming for entrepreneurs, ecosystem partners, students, and community members.
• CultiVAte: Ecosystem leader engagement and ecosystem network development to roadmap the region’s future.

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the …

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza …

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients …

News